Glycine

Glycine

SCHEMBL3205805

NCC(=O)[O-].O.[Na+]

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D

The experimentally established mechanism targets of Glycine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glycine SCHEMBL27577835 1.00 CA4 (0.50)
Glycine SCHEMBL27196 0.96
Glycine SCHEMBL2184513 0.96 CA4 (0.53)
Glycine SCHEMBL10725312 0.96 CA4 (0.53)
Glycine SCHEMBL3216076 0.92 CA4 (0.44)
Glycine SCHEMBL20239631 0.92 CA4 (0.44)
Glycine SCHEMBL20239641 0.92
Glycine SCHEMBL20239648 0.92 CA4 (0.44)
Glycine SCHEMBL1483142 0.92 CA4 (0.44)
Glycine SCHEMBL15842973 0.92 CA4 (0.44)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119082815-A Platinum electroplating solution, preparation method thereof and application thereof in wafer electroplating 昆山一鼎工业科技有限公司 2024-12-06 CN claimed
CN-118668195-B Electroless platinating solution, preparation method thereof and application thereof in wafer electroless platinating 昆山一鼎工业科技有限公司 2024-11-26 CN claimed
CN-118668195-A Electroless platinating solution, preparation method thereof and application thereof in wafer electroless platinating 昆山一鼎工业科技有限公司 2024-09-20 CN claimed
EP-4206645-B1 METHOD AND APPARATUS FOR REMOVING OR REDUCING FORMATION OF PRECIPITATES GENERATED IN HEMATOXYLIN SOLUTIONS VENTANA MED SYST INC (US) 2026-03-11 EP disclosed
US-20250213645-A1 PHARMACEUTICAL COMPOSITION FOR MODULATING IMMUNE RESPONSE L-Base Co., Ltd. (KR) 2025-07-03 US disclosed
CN-119082815-A Platinum electroplating solution, preparation method thereof and application thereof in wafer electroplating 昆山一鼎工业科技有限公司 2024-12-06 CN disclosed
CN-118668195-B Electroless platinating solution, preparation method thereof and application thereof in wafer electroless platinating 昆山一鼎工业科技有限公司 2024-11-26 CN disclosed
CN-118668195-A Electroless platinating solution, preparation method thereof and application thereof in wafer electroless platinating 昆山一鼎工业科技有限公司 2024-09-20 CN disclosed
US-20240207355-A1 PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF ANTICANCER DRUG L-Base Co., Ltd. (KR) 2024-06-27 US disclosed
EP-4062974-B1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER L BASE CO LTD (KR) 2024-05-08 EP disclosed
EP-4335452-A1 PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF ANTICANCER DRUG L-Base Co., Ltd. (KR) 2024-03-13 EP disclosed
CN-1816390-A Sol containing titanium dioxide, thin film formed therefrom and production process of the sol SHOWA DENKO KK (JP) 2006-08-09 CN disclosed
US-20060160754-A1 Glycyrrhizin high-concentration preparation NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) 2006-07-20 US disclosed
EP-1676580-A1 GLYCYRRHIZIN HIGH-CONCENTRATION PREPARATION Nippon Zoki Pharmaceutical Co. Ltd. (JP) 2006-07-05 EP disclosed
EP-1644115-A2 SOL CONTAINING TITANIUM DIOXIDE, THIN FILM FORMED THEREFROM AND PRODUCTION PROCESS OF THE SOL Showa Denko K.K. (JP) 2006-04-12 EP disclosed
WO-2005003035-A2 SOL CONTAINING TITANIUM DIOXIDE, THIN FILM FORMED THEREFROM AND PRODUCTION PROCESS OF THE SOL SHOWA DENKO K.K. (JP) 2005-01-13 WO disclosed
EP-0876385-B1 TOPIRAMATE IMMUNOASSAY, AS WELL AS ANALOGS AND ANTIBODIES OPUS DIAGNOSTICS INC (US) 2000-10-18 EP disclosed
US-5952187-A ANTIEPILEPTIC AGENT ANALOG DERIVATIZED AT THE SULFAMATE MOIETY OR THE 9-CARBON METHYL GROUP TO ADD LABEL FOR USE IN IMMUNOASSAYS OR TO ADD CARRIER FOR USE AS IMMUNOGEN; FOR MONITORING SERUM OR PLASMA LEVELS OF DRUG OXIS INTERNATIONAL, INC. (US) 1999-09-14 US disclosed
EP-0876385-A1 TOPIRAMATE IMMUNOASSAY, AS WELL AS ANALOGS AND ANTIBODIES Oxis International, Inc. (US) 1998-11-11 EP disclosed
WO-1997019950-A1 TOPIRAMATE IMMUNOASSAY, AS WELL AS ANALOGS AND ANTIBODIES OXIS INTERNATIONAL, INC. (US) 1997-06-05 WO disclosed